Trichostatin A increases radiosensitization of tongue squamous cell carcinoma via miR‑375

Oncol Rep. 2017 Jan;37(1):305-312. doi: 10.3892/or.2016.5261. Epub 2016 Nov 18.

Abstract

Trichostatin A (TSA), a histone deacetylase inhibitor, is used as an anti-carcinogenic and radiosensitizing agent in various cancers. However, the role and mechanism underlying its radiosensitization of tongue squamous cell carcinoma (TSCC) remains unclear. Thus, in this study we aimed to confirm the promotion of miR‑375 expression by TSA, and to investigate the effects of TSA and miR‑375 in the radiosensitivity of TSCC cells. The results showed that TSA had significant radiosensitizing effects on TSCC cells and miR‑375 overexpression had effects similar to TSA in sensitizing these cells to radiotherapy. By contrast, miR‑375 knockdown attenuated apoptosis induced by radiation combined with TSA. Mechanistically, the histone acetylation status of the miR‑375 promoter region was increased by TSA, resulting in the upregulation of miR‑375, which led to a decline of PDK1 and phosphorylated AKT. Taken together, our data suggest that TSA increases the radiosensitization and apoptosis in TSCC cells at least partially via miR‑375, and TSA or miR‑375 in combination with radiotherapy may provide a valuable approach for the treatment of TSCC.

MeSH terms

  • Apoptosis / drug effects
  • Apoptosis / radiation effects
  • Carcinoma, Squamous Cell / drug therapy
  • Carcinoma, Squamous Cell / genetics
  • Carcinoma, Squamous Cell / radiotherapy*
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Cell Proliferation / radiation effects
  • Histone Deacetylase Inhibitors / pharmacology
  • Histones / metabolism
  • Humans
  • Hydroxamic Acids / pharmacology*
  • MicroRNAs*
  • Phosphorylation / drug effects
  • Promoter Regions, Genetic / drug effects
  • Proto-Oncogene Proteins c-akt / metabolism
  • Radiation-Sensitizing Agents / pharmacology*
  • Tongue Neoplasms / drug therapy
  • Tongue Neoplasms / genetics
  • Tongue Neoplasms / radiotherapy*

Substances

  • Histone Deacetylase Inhibitors
  • Histones
  • Hydroxamic Acids
  • MIRN375 microRNA, human
  • MicroRNAs
  • Radiation-Sensitizing Agents
  • trichostatin A
  • Proto-Oncogene Proteins c-akt